Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Ohtsu

Showing results (81-90 of 107) with videos related to

Pageof 11
Sort By:
British Journal of Cancer|May 24, 2012
KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancerY Kawamoto, K Tsuchihara, T Yoshino, et al.
Cancer Chemotherapy and Pharmacology|December 17, 2010
Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumorsT Doi, H Murakami, A Ohtsu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2010
Phase I trial of combination chemotherapy with docetaxel, cisplatin and S-1 (TPS) in patients with locally advanced or recurrent/metastatic head and neck cancerM Tahara, K Araki, S Okano, et al.
ESMO Open|June 10, 2022
Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysisT Yoshino, E Van Cutsem, J Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2004
Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LVK Shirao, P M Hoff, A Ohtsu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancerK Shirao, Y Shimada, H Kondo, et al.
ESMO Open|December 1, 2022
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancerE Van Cutsem, H Hochster, K Shitara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 1998
Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinumN Boku, K Chin, K Hosokawa, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Cancer registry as external control data for regulatory submission in JapanH Bando, N Okita, Y Sakamoto, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
ARCAD-Asia initiative: leveraging yesterday's data for tomorrowY Takeda, T Misumi, H Bando, et al.
Pageof 11

Showing results (81-90 of 107) with videos related to

Sort By:
Pageof 11
British Journal of Cancer|May 24, 2012
KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancerY Kawamoto, K Tsuchihara, T Yoshino, et al.
Cancer Chemotherapy and Pharmacology|December 17, 2010
Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumorsT Doi, H Murakami, A Ohtsu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2010
Phase I trial of combination chemotherapy with docetaxel, cisplatin and S-1 (TPS) in patients with locally advanced or recurrent/metastatic head and neck cancerM Tahara, K Araki, S Okano, et al.
ESMO Open|June 10, 2022
Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysisT Yoshino, E Van Cutsem, J Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2004
Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LVK Shirao, P M Hoff, A Ohtsu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancerK Shirao, Y Shimada, H Kondo, et al.
ESMO Open|December 1, 2022
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancerE Van Cutsem, H Hochster, K Shitara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 1998
Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinumN Boku, K Chin, K Hosokawa, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Cancer registry as external control data for regulatory submission in JapanH Bando, N Okita, Y Sakamoto, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
ARCAD-Asia initiative: leveraging yesterday's data for tomorrowY Takeda, T Misumi, H Bando, et al.
Pageof 11